Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes

Br J Pharmacol. 2010 Jul;160(5):1092-104. doi: 10.1111/j.1476-5381.2010.00753.x.

Abstract

Background and purpose: Arteries from hypertensive subjects are reportedly hyperresponsive to 5-hydroxytryptamine (5-HT), but it remains unclear whether this is true in chronic type 2 diabetes. We have assessed responses to 5-HT shown by mesenteric arteries from type 2 diabetic ob/ob mice (27-32 weeks old) and have identified the molecular mechanisms involved.

Experimental approach: Contractions of mesenteric rings to 5-HT were examined in vitro. Activation of mesenteric RhoA, Rho kinase and Src was measured by Western blotting or by modified enzyme-linked immunosorbent assay.

Key results: Concentration-dependent contractions to 5-HT were greater in mesenteric rings from the ob/ob than in those from the age-matched control ('Lean') group. In each group, there was no significant change in the 5-HT-induced contractions after inhibition of nitric oxide synthase (with N(G)-nitro-L-arginine), of cyclooxygenase (with indomethacin) or of protein kinase C (with chelerythrine). However inhibition of the MEK/ERK pathway (with PD98059) decreased the response to 5-HT. Although the diabetes-related enhancement of the 5-HT response was preserved with each of these inhibitors, enhancement was abolished by a Rho kinase inhibitor (Y27632) and by Src kinase inhibitors (PP1 analogue or Src kinase inhibitor I). 5-HT-induced activation of RhoA, Rho kinase and Src kinase in mesenteric arteries was greater in the ob/ob than in the Lean group, but the expression of RhoA, Rho kinase isoforms and Src did not differ between these groups.

Conclusions and implications: These results suggest that the enhancement of 5-HT-induced contraction in mesenteric arteries from ob/ob mice may be attributable to increased activation of RhoA/Rho kinase and Src kinase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Diabetes Mellitus, Experimental / physiopathology*
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • In Vitro Techniques
  • MAP Kinase Signaling System / drug effects
  • Mesenteric Arteries / physiopathology*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Obese
  • Muscle Contraction / drug effects
  • Muscle Contraction / physiology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Prostaglandin-Endoperoxide Synthases / drug effects
  • Protein Kinase C / antagonists & inhibitors
  • Serotonin / pharmacology*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • rho-Associated Kinases / antagonists & inhibitors
  • rho-Associated Kinases / physiology*
  • rhoA GTP-Binding Protein / physiology
  • src-Family Kinases / antagonists & inhibitors
  • src-Family Kinases / physiology*

Substances

  • Enzyme Inhibitors
  • Serotonin
  • Nitric Oxide Synthase
  • Prostaglandin-Endoperoxide Synthases
  • src-Family Kinases
  • rho-Associated Kinases
  • Protein Kinase C
  • rhoA GTP-Binding Protein